Clinical experience of using high‐flow nasal cannula oxygen therapy for treating SARS‐CoV‐2019 (COVID‐19)‐infected patients in the emergency medicine ward

Abstract Introduction During the fifth‐wave outbreak of COVID‐19 in Hong Kong in 2022, North Lantau Hospital (NLTH), as the designated COVID‐19 hospital in Kowloon West Cluster, offered medical support for COVID‐19 patients in the district and nearby isolation facilities. Intensive care units (ICUs) at that time were overwhelmed by the surge of patients. Training was provided to emergency medicine ward (EMW) staff for providing high‐flow nasal cannula (HFNC) oxygen therapy to severely ill COVID‐19 patients who developed hypoxemia and respiratory failure in a non‐ICU setting. Method Descriptive sharing of the clinical experience in managing patients with COVID‐19 infection who were admitted to the EMW of NLTH from March 1, 2022, to September 30, 2023, and required HFNC oxygen therapy. The associated factors for the clinical outcomes were also evaluated. Results During the study period, 22 COVID‐19 patients with hypoxemia and respiratory failure were offered HFNC oxygen therapy in the EMW of NLTH. All were elderly patients with an average age of 83.6 years and a background of multiple medical illnesses. Staff in the EMW were able to provide appropriate care for patients receiving HFNC after short training. There were no complications associated with the use of HFNC in any of the patients. Six (27.3%) patients survived their hospital admission. In general, patients with a higher ratio of peripheral saturation of oxygen (SpO 2 ) and fraction of inspired oxygen (FiO 2 ) (SF ratio) after the initiation of HFNC oxygen therapy were more likely to survive. Conclusion The use of HFNC for COVID‐19‐related acute hypoxemic respiratory failure is a feasible option for care in EMW settings. Our experience suggested that HFNC served as an initial life‐sustaining treatment for elderly COVID‐19 patients with fair premorbid status who were unlikely to benefit from invasive positive‐pressure ventilation, and their prognoses could be more objectively assessed by serial monitoring of the SF ratio.

Authors

Publication Details

Journal
Hong Kong Journal of Emergency Medicine
Published
2025-02-01
DOI
https://doi.org/10.1002/hkj2.70004
Primary Topic
Respiratory Support and Mechanisms
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Clinical experience of using high‐flow nasal cannula oxygen therapy for treating SARS‐CoV‐2019 (COVID‐19)‐infected patients in the emergency medicine ward

Oi Fung Wong, Safiyyah Nok Sze Lui, Shing Ko, Ka Hung Chan et al.
Hong Kong Journal of Emergency Medicine
Respiratory Support and Mechanisms
article

Clinical experience of using high‐flow nasal cannula oxygen therapy for treating SARS‐CoV‐2019 (COVID‐19)‐infected patients in the emergency medicine ward

Oi Fung Wong, Safiyyah Nok Sze Lui, Shing Ko, Ka Hung Chan, K. Wong, Yee Yung Ng
article en

Abstract

Abstract Introduction During the fifth‐wave outbreak of COVID‐19 in Hong Kong in 2022, North Lantau Hospital (NLTH), as the designated COVID‐19 hospital in Kowloon West Cluster, offered medical support for COVID‐19 patients in the district and nearby isolation facilities. Intensive care units (ICUs) at that time were overwhelmed by the surge of patients. Training was provided to emergency medicine ward (EMW) staff for providing high‐flow nasal cannula (HFNC) oxygen therapy to severely ill COVID‐19 patients who developed hypoxemia and respiratory failure in a non‐ICU setting. Method Descriptive sharing of the clinical experience in managing patients with COVID‐19 infection who were admitted to the EMW of NLTH from March 1, 2022, to September 30, 2023, and required HFNC oxygen therapy. The associated factors for the clinical outcomes were also evaluated. Results During the study period, 22 COVID‐19 patients with hypoxemia and respiratory failure were offered HFNC oxygen therapy in the EMW of NLTH. All were elderly patients with an average age of 83.6 years and a background of multiple medical illnesses. Staff in the EMW were able to provide appropriate care for patients receiving HFNC after short training. There were no complications associated with the use of HFNC in any of the patients. Six (27.3%) patients survived their hospital admission. In general, patients with a higher ratio of peripheral saturation of oxygen (SpO 2 ) and fraction of inspired oxygen (FiO 2 ) (SF ratio) after the initiation of HFNC oxygen therapy were more likely to survive. Conclusion The use of HFNC for COVID‐19‐related acute hypoxemic respiratory failure is a feasible option for care in EMW settings. Our experience suggested that HFNC served as an initial life‐sustaining treatment for elderly COVID‐19 patients with fair premorbid status who were unlikely to benefit from invasive positive‐pressure ventilation, and their prognoses could be more objectively assessed by serial monitoring of the SF ratio.

Hong Kong Journal of Emergency MedicineVol. 32(1)
Openalex Percentile: Top 96%
Respiratory Support and Mechanisms
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.